PPT-Improving Therapy Outcomes in Relapsed/Refractory
Author : celsa-spraggs | Published Date : 2016-12-10
Hodgkin Lymphoma Program Objectives Brentuximab Vedotin in Hodgkin Lymphoma Brentuximab Vedotin in Patients With RR HL Brentuximab Vedotin Adverse Events Nivolumab
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "Improving Therapy Outcomes in Relapsed/R..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Improving Therapy Outcomes in Relapsed/Refractory: Transcript
Hodgkin Lymphoma Program Objectives Brentuximab Vedotin in Hodgkin Lymphoma Brentuximab Vedotin in Patients With RR HL Brentuximab Vedotin Adverse Events Nivolumab in RelapsedRefractory HL Pembrolizumab in RelapsedRefractory HL. Agents . for . Indolent . L. ymphoma . and . Mantle Cell Lymphoma. . Stephen Ansell, MD, PhD. Mayo Clinic. Tiacci. et al, Nature . Reviews Cancer 6, 437-. 448, 2006.. Would we expect mantle cell lymphoma and follicular lymphoma to respond to similar agents?. lymphoblastic leukemia. . Franco Locatelli, Martin Schrappe, Maria Ester Bernardo and Sergio Rutella. Blood.August. 15, 2012. . . Relapsed ALL. 80-85% of ALL: cure- prognostic factors -risk-oriented treatment protocols.. Topics. Current Treatment Options for Relapsed/Refractory Multiple Myeloma. Topics. Relapsed/Refractory MM. Treatment Goals and Strategies. Relapsed/Refractory MM. Exposure to Stem Cell Toxic Agents Not An Issue for Most Patients . 5 Multiple Myeloma SANDRA E. KURTIN, RN, MS, AOCN therapy in relapsed/refractory myeloma: . A UK multi-centre experience. Neil Rabin. Consultant Haematologist. o. n behalf of Dr Nicola . Maciocia. University College London Hospitals, UK. 4. th. November 2015. IWCLL Criteria for Treating CLL. Other Considerations at Relapse. Risk Factors at Relapse. IGHV . Status Affects Clinical Course. Case 1: 65-Year-Old Man. Assessing This Patient's Options. TP53 . Mutation/del(17p) and CIT. ASH Review 2012. Stephen Spurgeon (spurgeos@ohsu.edu). Disclosures. Speakers Bureau: GSK, . Millenium. , . Cephalon. CLL: Pertinent Topics. ASH treatment updates. James DF, et al. ASH 2011. Abstract 291.. MSc. University of Tennessee College of . Health Sciences. Memphis, TN. . . Learning Objectives. Upon completion, participants should be able to:. Review treatment regimens for patients with relapsed ALL. Case Discussion A 64-year old woman diagnosed with monoclonal gammopathy of undetermined significance (MGUS ) in September 2015 She has been monitored over time and has had a slight increase in her proteins. Chimeric Antigen Receptor Tcell TherapyClinical Guideline Effective August 4, 2022 ��Table of Contents��THIS DOCUMENT IS PROPRIETARY AND CONFIDENTIAL TO OPTUMUnauthorized u Helpline: 800 500 9976 | helpline@lymphoma.org Understanding LymphomaDiffuse Large B-Cell Lymphoma: Relapsed/Refractory Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin l Meletios Dimopoulos,. 1. Hang Quach,. 2. Maria-Victoria Mateos,. 3. Ola Landgren,. 4. Xavier Leleu,. 5. David Siegel,. 6. Katja Weisel,. 7. Maria Gavriatopoulou,. 8. Albert Oriol,. 9. Neil Rabin,. Status Epilepticus. . Vikki Norman, Ananth Kumar and Philip Knight. . +. Peripheral T-Cell Lymphoma: A Phase 2 Study (LuminICE-203). Alison Moskowitz. 1. , Andreas Harstrick. 2. , Michael Emig. 2. , Andre Overesch. 2. ,. . Sheena Pinto. 2. , . Paulien Ravenstijn. 2.
Download Document
Here is the link to download the presentation.
"Improving Therapy Outcomes in Relapsed/Refractory"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents
